| Filed On | Filing |
|---|---|
| 23 Mar 2026 |
8-K/A: Entry into a Material Definitive Agreement
This Settlement Agreement (“Agreement”) is entered into as of March 3, 2026 (the “Effective Date”) by and between, on the one hand, Genevant Sciences GmbH ( “Genevant”), a limited liability company organized under the laws of Switzerland... |
| 20 Dec 2023 |
8-K/A: Financial Statements and Exhibits
On December 14, 2023, Roivant Sciences Ltd. (“Roivant” or the “Company”) completed the previously announced sale (the “Transaction”) of all of the shares of capital stock it held in Telavant Holdings, Inc. (“Telavant”) to Roche Holdings,... |
| 28 Jun 2023 |
8-K/A: Results of Operations and Financial Condition
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provides Business Update |
Loading...
